S
S. Chowdhury Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
20 h-index
119 pubs
2,028 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
S. Chowdhury's research focuses on the pharmacological treatment of advanced prostate cancer and urothelial carcinoma. Their work investigates the efficacy and safety of various therapeutic agents, including apalutamide, rucaparib, and abiraterone acetate, often in combination with androgen deprivation therapy or other chemotherapeutic agents. Studies have examined specific patient populations, such as those with metastatic castration-sensitive prostate cancer, high-volume or low-volume disease, and older patients.
Further research has explored the association between treatment response, indicated by prostate-specific antigen (PSA) decline, and patient survival and clinical outcomes. Collaborations with researchers at the University of Arkansas for Medical Sciences and within Arkansas State University contribute to a body of work that has resulted in over 120 publications and more than 2,000 citations, with an h-index of 20. Additionally, Chowdhury has contributed to research on the prevalence of constipation in the adult population of Bangladesh.
Metrics
- h-index: 20
- Publications: 119
- Citations: 2,028
Selected Publications
-
Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2025)
-
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024)
Collaboration Network
Top Collaborators
Suneel Mundle
Janssen (Belgium) (BE)
6 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Showing 5 of 6 shared publications
Amitabha Bhaumik
Janssen (Belgium) (BE)
6 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Showing 5 of 6 shared publications
Neeraj Agarwal
Huntsman Cancer Institute (US)
5 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Anders Bjartell
Lund University (SE)
4 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
S. Brookman-May
Janssen (United States) (US)
4 shared publications
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Shane McCarthy
Janssen (United States) (US)
4 shared publications
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
K.N. Chi
4 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Hiroji Uemura
Kindai University (JP)
3 shared publications
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison
Andrea Juliana Gomes
Liga Contra el Cancer (PE)
3 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
Robert Given
Urology of Virginia (US)
3 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)
- Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
Axel S. Merseburger
University Hospital Schleswig-Holstein (DE)
3 shared publications
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
- 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
- Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
Mukta Nath
3 shared publications
- Symptoms and Prevalence of Constipation among Adult Population of Bangladesh
- Stress of the COVID-19 and its Consequences on Irritable Bowel Syndrome Patients in A Selected Tertiary Level Hospital in Bangladesh
- Double-balloon Enteroscopy, in the diagnosis and management of GI tract diseases at a tertiary level hospital.
Sanjay Adhikary
Arkansas State University
3 shared publications
In database
- Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
- Author response for "Thiazole-fused Androstenone and Ethisterone Derivatives: Potent β- and γ-Actin Cytoskeleton Inhibitors to Treat Melanoma Tumors"
- Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
Subrata Roy
Arkansas State University
3 shared publications
In database
- Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
- Author response for "Thiazole-fused Androstenone and Ethisterone Derivatives: Potent β- and γ-Actin Cytoskeleton Inhibitors to Treat Melanoma Tumors"
- Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
Shailesh Budhathoki
Arkansas State University
3 shared publications
In database
- Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
- Author response for "Thiazole-fused Androstenone and Ethisterone Derivatives: Potent β- and γ-Actin Cytoskeleton Inhibitors to Treat Melanoma Tumors"
- Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors
Similar Researchers
Based on overlapping research topics
Tom Menzies
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Health Disparities and Outcomes
Allison Wells
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Health Disparities and Outcomes
Tra Le
Arkansas State University
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Cancer-related molecular mechanisms research
Maham Bakhtyar
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Meta-analysis and systematic reviews
Shi‐Ming Tu
University of Arkansas for Medical Sciences
Prostate Cancer Treatment and Research
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Zainab Atiq
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Health Disparities and Outcomes